SEC EDGARAUG 211 min read$RGEN

Loeillot Olivier sold $977K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Loeillot Olivier

Published Aug 21, 2026, 8:06 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$RGEN

Neutral

medium confidence

Mentioned

$RGEN

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$RGENNeutralLow

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

Market read

A routine insider sale with limited trading relevance.

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RGENNeutralMedium confidence

Context

CEO Olivier Loeillot sold 5,426 shares for $976,680 via a 10b5‑1 plan, reducing his stake to 54,246 shares.

Expected impact

Potential minor downward pressure, likely within normal volatility range.

Evidence & confidence

The sale amount is under $1M and represents a small percentage of total holdings, limiting market impact.

Market effects

Sector

Minimal effect on biotech/healthcare sector; insider sales are routine.

Regional

No regional impact beyond investor perception of RGEN.

Global

Limited global relevance; only relevant to RGEN shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a bearish signal.

Key entities

Person
Loeillot Olivier
Chief Executive Officer of Repligen Corp.
Company
Repligen Corp
Biopharmaceutical company listed on NASDAQ under ticker RGEN.

Read at source ← All news

SEP 4

$BLFSMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min

SEP 4

$RGENHighAI 9/10

What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share

Repligen (RGEN) filed an amended Form S-4 to register shares for its acquisition of BioLife Solutions. The deal offers $11.25 in cash plus 0.1442 Repligen shares per BioLife share, pending approvals. The merger is subject to shareholder and regulatory approvals, with a special meeting scheduled for October 5, 2026. The exchange ratio is fixed, but the value of the share portion will fluctuate with Repligen's stock price.

stocktitan.net2 min

AUG 31

$IQVMedAI 8/10

Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment

Azenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.

finance.yahoo.com3 min

AUG 27

$RGENHighAI 8/10

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).

finance.yahoo.com2 min

AUG 25

$MRKHighAI 8/10

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

yahoo.com3 min

AUG 20